12 Partners (4 research institutes, 3 SMEs and 5 cancer clinics) from 6 different European and associated countries.
AOP is coordinating the project and leads the clinical and scientific research for prospective studies.
UPM is the Technical Coordinator and leads the semantic framework and the overall BD2Decide design.
VUMC is responsible for the design of the clinical study and the prediction modelling.
UDUS contributes to the clinical studies with patients' data for validation of the project research.
INT leads the clinical research in genomics, the genomics data collection and data analysis.
Fraunhofer offers solutions for tumor segmentation and image features extraction.
ATC leads the patients' data visualization and virtual representation tools.
All-in-Image leads the Big Data Infrastructure and the integration of population and other data for analysis.
MAASTRO leads the CT scan radiomics task and participates in the clinical study.
POLIMI leads the MRI scan radiomics task and the identification of radiomics signatures from MRI and DWI-MRI scans.
MME coordinates the exploitation and communication strategy and the actions for maximizing project impact.
Unipr contributes to the clinical study setup and execution and the validation of the project results.
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 689715